Paper Details

  1. Home
  2. Paper Details

Elagolix for endometriosis: all that glitters is not gold.

Author: , BarbaraGiussy, BuggioLaura, SomiglianaEdgardo, VercelliniPaolo, ViganòPaola

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Elagolix is a new drug approved by the FDA to treat endometriosis. It works by reducing estrogen levels. The amount of pain relief is dose-dependent, and lower doses may result in less pain relief but fewer side effects. The drug is expensive, and long-term use may require additional therapies.
Paper Details　
Original Abstract of the Article :
Elagolix, an orally active non-peptidic GnRH antagonist, has been approved by the Food and Drug Administration for the management of moderate to severe pain associated with endometriosis. As the degree of ovarian suppression obtained with elagolix is dose-dependent, pain relief may be achieved by mo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/humrep/dey368

データ提供：米国国立医学図書館（NLM）

Elagolix for Endometriosis: A New Desert Oasis?

This study examines the potential benefits and limitations of elagolix, a new GnRH antagonist, for treating endometriosis, a chronic condition affecting women that can cause debilitating pain and infertility. The researchers acknowledge the promise of elagolix as a potential new treatment option for endometriosis, but they also highlight the need for careful consideration of its cost-effectiveness and the importance of weighing the potential benefits against the potential risks.

The Price of Relief

The study explores the cost-effectiveness of elagolix, a crucial consideration in the healthcare landscape. The authors point out that the high cost of elagolix, like a mirage in the desert, can hinder access to treatment for many women. They raise ethical concerns about the allocation of healthcare resources, suggesting that the cost of a new drug should be weighed against the potential benefits and the availability of alternative, more affordable treatment options.

The Importance of Evidence-Based Decision-Making

The study emphasizes the need for more comprehensive evidence-based research to assess the efficacy and cost-effectiveness of elagolix. It's like a desert explorer venturing into uncharted territory, carefully collecting data and observations to guide their journey. By conducting pragmatic trials comparing elagolix with existing treatment options, researchers can provide clinicians with a more complete understanding of the drug's true value and its place in the treatment landscape for endometriosis.

Dr. Camel's Conclusion

This study reminds us that the search for effective treatments for endometriosis is an ongoing journey. While elagolix offers a potential new oasis in the desert of this condition, it's crucial to consider its cost-effectiveness and compare it to existing treatment options. By making evidence-based decisions, we can ensure that women have access to the best possible care, regardless of their financial resources.

Date :
  1. Date Completed 2020-06-19
  2. Date Revised 2020-06-19
Further Info :

Pubmed ID

30551159

DOI: Digital Object Identifier

10.1093/humrep/dey368

Related Literature

Article Analysis
・Side Effects of elagolix
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.